

## ORIGINAL RESEARCH

# Short-term Side Effects of mRNA-based COVID-19 Vaccine Among Jordanian Population; a Cross-sectional Study

Razan I. Nassar<sup>1\*</sup>

1. Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.

Received: October 2022; Accepted: December 2022; Published online: 12 February 2023

**Abstract:** **Introduction:** One type of the developed COVID-19 vaccines that received emergency permission and was approved by the food and drug administration (FDA) is the mRNA-based vaccine. The aim of this study is to gather information on the Jordanian population's experience with the vaccine's side effects. **Methods:** The study objectives were addressed through a cross-sectional study, which collected information regarding the short-term side effects experienced by the vaccinated individuals within one month following the injection of an mRNA-based COVID-19 vaccine. Data collection was carried out in August 2021. Participants were invited to take part in a self-administered web-based survey created using Google Forms. **Results:** Among the study's participants (n= 533), about 56% experienced side effects after the first dose of the mRNA-based COVID-19 vaccine. The most commonly reported side effects after the first dose were sore arm at the injection site (91.6%), and fatigue (83.06%). The female gender was significantly associated with experiencing fatigue, discomfort, chills, and hair loss. Being over 30 years old was significantly associated with experiencing cough. Being a smoker was significantly associated with experiencing shortness of breath and gastrointestinal symptoms. **Conclusion:** The mRNA-based COVID-19 vaccine side effects were common, yet, mild, local, and self-limited. The local pain at the injection site was the most commonly reported side effect. Hopefully, the study's findings will aid in lowering resistance to vaccination.

**Keywords:** Coronavirus; COVID-19; adverse effects; vaccines; mRNA vaccine; COVID-19 vaccines; Jordan

**Cite this article as:** I. Nassar R. Short-term Side Effects of mRNA-based COVID-19 Vaccine Among Jordanian Population; a Cross-sectional Study. Arch Acad Emerg Med. 2023; 11(1): e22. <https://doi.org/10.22037/aaem.v11i1.1850>.

## 1. Introduction

In December 2019, the novel coronavirus (SARS-CoV-2) was first recognized in Wuhan, China. It causes a highly infectious disease referred to as COVID-19 (1). The COVID-19 has spread globally to turn into a worldwide pandemic (2). Healthcare providers, policymakers, governments, and researchers were eagerly working around the clock to provide sufficient prevention and treatment modalities to fight the pandemic (3). Worldwide, several preventive measures were imposed by the governments in order to reduce the spread of the virus and the burden on the healthcare sector; for example, quarantine and social distancing were imposed, also wearing a face mask was made mandatory in public places (4, 5).

The public health emergency needed urgent efforts to develop and test the vaccines to combat the COVID-19 pan-

demic (3). Thus, several vaccines were developed and granted emergency approval (6). One type of the developed vaccines is the mRNA-based COVID-19 vaccine, which was approved by the United States Food and Drug Administration in December 2020 (7). To get fully vaccinated with the mRNA-based vaccine, two doses are required; the second dose must be administered at least three weeks after the first dose. The vaccine can provide efficient protection one week after the second dose (8).

In January 2021, Jordan was one of the first countries to launch vaccination campaigns, giving emphasis to healthcare professionals and the elderly (9). Despite the government's continuous attempts to guarantee that most of the population is vaccinated; myths, fear, safety concerns, and negative beliefs have adversely shaped the perception of the public, which in turn affected the percentage of infected individuals.

Variation in public awareness and perception toward vaccines is generally documented (10-12). Furthermore, hesitancy is another major factor that influenced the decision of the individual whether to receive the vaccine or not (11, 12). Hesitancy associated with getting vaccinated is com-

\* **Corresponding Author:** Razan I. Nassar; Applied Science Private University, Amman 11931, Jordan, P. O. Box 166, Email: [r\\_nassar@asu.edu.jo](mailto:r_nassar@asu.edu.jo), Phone: W +9626 5609999, M +962 799770094, ORCID: <https://orcid.org/0000-0001-8952-0376>.

mon, partly due to the fact that the COVID-19 vaccines were rapidly developed (13). Concerns and fears of individuals who are hesitant to vaccinate should be addressed. This calls for urgent public transparency and engagement (12).

Thus, it is crucial to collect data regarding COVID-19 vaccines' side effects in order to educate and clarify to the public what to anticipate post-vaccination. This information may contribute to increasing confidence in COVID-19 vaccines, as well as, decreasing hesitancy.

Hence, the aim of this study is to gather information on the Jordanian population's experience with the COVID-19 vaccine's immediate side effects.

## 2. Methods

### 2.1. Study design and settings

The study objectives were addressed through a cross-sectional study, which was performed to collect information regarding the short-term side effects experienced by the vaccinated individuals within one month following the injection of an mRNA-based COVID-19 vaccine. Data collection was carried out in August 2021. Participants were invited to take part in a self-administered web-based survey created using Google Forms. The survey was adjusted in a way that allows the participant to send one response only.

Ethical approval for this study was obtained from the Institutional Review Board Committee at the Faculty of Pharmacy, Applied Science Private University (Ethics code: 2021-PHA-31). Participation in the study was voluntary. Informed consent to participate in the study was provided by participants.

### 2.2. Participants

Eligibility criteria included residing in Jordan, and having received at least one dose of the mRNA-based COVID-19 vaccine. Individuals living in any geographic area were allowed to participate in the study. Participants should have the ability to provide their information by completing the online survey.

### 2.3. Data gathering

The survey items were selected based on the existing information regarding the side effects of the mRNA-based COVID-19 vaccine (Pfizer-BioNTech®). Following an extensive review of the literature on PubMed, Google Scholar, and other databases, the first draft of the survey was developed (8, 14, 15). The survey questions were reviewed to merge concepts and eliminate unrelated items.

Three experts in the field reviewed the first draft to ensure its face and content validity, then the survey was updated based on their feedback. Assessment criteria were sent to them (appropriateness of the words used, clarity of items, suitability of content, consistency of survey style and its layout). They

informed the research team that the survey is clear, comprehensive, the items are relevant to the study objectives and suitable for the study's aim. Moreover, they confirmed that the study survey is free from difficult terminology and medical jargon.

To assess the clarity of words and item comprehension, a pilot study was conducted. The pilot study participants were excluded from the analysis of the current study, and additional amendments were conducted based on their suggestions. To finalize, the questions were re-evaluated to make them concise and suitable for online administration (format, sequencing, general clarity, and graphic layout).

The final developed survey was organized into two major sections addressing the domains of interest. The first section included items to collect participants' demographic data, such as gender, age, marital status, educational level, employment, living place, and nationality. Additionally, the following information was also collected; whether they were smokers, had any chronic disease(s), whether they were using any medication(s), and if they were previously infected with COVID-19. The second section included items that aimed to collect information regarding the side effects experienced following the injection of mRNA-based COVID-19 vaccine; the following data were collected: the date of vaccination (month), the number of doses that were taken (one or two doses), and the side effects that were experienced after receiving each dose. Additionally, in this section, participants were asked if they needed hospitalization within a month of receiving the vaccine, and they were requested to select the dose that caused the most severe side effects.

### 2.4. Survey implementation

Study participants were recruited through social media (mainly Facebook and WhatsApp). As the first step in participants' selection, they were asked if they had received the first dose of the mRNA-based COVID-19 vaccine. This question should be answered with 'Yes' in order to be able to open the survey. Eligible participants who indicated a willingness to participate in this study were also able to open a link to see the study's ethics committee approval letter, and afterward, they were able to complete the survey.

Communication between the researcher and the participants was established via e-mail when needed. The survey was designed to take less than five minutes to be completed.

### 2.5. Statistical analyses

The sample size was determined based on population and the number of vaccinated individuals in Jordan. It was calculated to be a minimum of 384 participants, using a margin of error of 5%, a confidence level of 95%, and a response distribution of 50% (16).

The survey responses were coded and entered into a cus-

**Table 1:** Demographic characteristics of the studied participants (n= 533)

Parameter	Number (%)
<b>Gender</b>	
Male	119 (22.3)
Female	414 (77.7)
<b>Age (year)</b>	
< 18	8 (1.5)
18-29	219 (41.1)
30-39	195 (36.6)
40-49	75 (14.1)
50-59	27 (5.1)
≥ 60	9 (1.7)
<b>Marital Status</b>	
Married	294 (55.0)
Single	217 (40.7)
Divorced	20 (3.8)
Widowed	2 (0.4)
<b>Living place</b>	
Amman (the Capital)	403 (75.6)
Other cities	130 (24.4)
<b>Nationality</b>	
Jordanian	491 (92.1)
Non-Jordanian	42 (7.9)
<b>Educational level</b>	
Primary school	6 (1.1)
Some high school	27 (5.1)
High school diploma	35 (6.6)
Bachelor's degree	367 (68.9)
Postgraduate degree (Master's or PhD)	98 (18.4)
<b>Employment</b>	
Employed	282 (52.9)
Not employed	236 (44.3)
Retired	15 (2.8)
<b>Smoker</b>	
Yes	154 (28.9)
No	365 (68.5)
Previous smoker	14 (2.6)

tomized database using the Statistical Package for the Social Sciences (SPSS), Version 24.0 (IBM Corp., Armonk, New York, USA). Qualitative variables were presented as percentages. Fisher's exact test was used to assess the association between each side effect after the first dose of the mRNA-based COVID-19 vaccine and participants' gender, age, and smoking status. The p-value cutoff for significance was established at 0.05.

### 3. Results

#### 3.1. Baseline characteristics of studied cases

The survey was distributed to 545 participants; however, 12 individuals refused to participate in the current study leaving a response rate of 97.8%. The detailed demographic characteristics of the participants are listed in Table 1. The majority

of the study's participants were female (77.7%), about 43% of the participants were less than 30 years old, more than half of the participants (55.0%) were married, 92.1% had a Jordanian nationality, and 87.3% had a bachelor's or postgraduate degree. More than half of the participants were employed (52.9%), and about one-third of the participant were smokers (28.9%).

The most common comorbidity among the participants was allergy (19.5%). The percentages of other comorbidities were low, ranging from 0.4% (chronic obstructive pulmonary disease) to 6.6% (thyroid diseases). More than half of the participants (52.7%) were not infected prior to receiving the mRNA-based COVID-19 vaccine, whereas, 37.9% had been affected with COVID-19 prior to vaccination, and the remaining (9.4%) were unsure. In May 2021, 26.1% of the study's participants had received the first dose of the mRNA-based COVID-19 vaccine, while the lowest percentage was reported in January 2021 (2.1%).

#### 3.2. Side effects


Regarding the side effects after the first dose of the mRNA-based COVID-19 vaccine, 300 (56.3%) cases reported experiencing various side effects. The most common side effect that was reported by the participants was sore arm at the site of injection (91.6%). Fatigue and tiredness (83.6%), discomfort (69.6%), muscle/joint pain (60.3%), drowsiness (59.0%), and headache (57.6%) were reported by more than half of the participants (Figure 1).

Association between side effects after the first dose of the mRNA-based COVID-19 vaccine and participants' gender, age, and smoking status were investigated. As shown in Figure 2, there is a significant association between the female gender and experiencing fatigue ( $p = 0.033$ ), discomfort ( $p = 0.013$ ), chills ( $p = 0.003$ ), and hair loss ( $p\text{-value} = 0.017$ ). A significant association was found between being older than 30 and experiencing cough ( $p = 0.046$ ). Furthermore, a significant association was found between being a smoker and experiencing shortness of breath ( $p = 0.042$ ), and gastrointestinal symptoms ( $p = 0.049$ ).

Out of the 533 participants, 402 (75.4%) had received the second dose of the mRNA-based COVID-19 vaccine. Among those participants ( $n = 402$ ), about 66.0% ( $n = 267$ ) experienced side effects after the second dose of the mRNA-based COVID-19 vaccine.

The most common side effect that was reported by the participants after the second dose was a sore arm at the site of injection (88.8%). Fatigue, discomfort, muscle/joint pain, headache, and drowsiness were also reported by more than half of the participants (Figure 1).

More than half (58.8%) of the study participants who had side effects after both doses stated that the second dose was accompanied by more severe side effects; in contrast, 24.7%




**Figure 1:** Side effects reported by the study's participants after receiving the first dose (n= 300) and the second dose (n= 267) of the mRNA-based COVID-19 vaccine (the difference was only significant for drowsiness (p = 0.033)).

chose the first dose, and 16.5% said there was no difference between the two doses.

A statistically significant increase ( $p < 0.000$ ) was found in the proportion of the participants who experienced side ef-

fects after the second dose (66.4%) compared to the first dose. Moreover, as shown in figure 1, drowsiness was the only side effect that showed a significant difference in the proportion of participants who experienced it following the first and



**Figure 2:** Association between experiencing side effects and gender, age, and smoking status among the study's participants.

the second dose of the mRNA-based COVID-19 vaccine ( $p = 0.033$ ).

#### 4. Discussion

This is the first cross-sectional study conducted on the Jordanian population to specifically assess the side effects of mRNA-based COVID-19 vaccine. Receiving the COVID-19 vaccine is a major intervention toward containing the pandemic. However, it has been faced with hesitancy (17-19). Limited data about the COVID-19 vaccines development account for the high level of uncertainty and hesitancy toward COVID-19 vaccine acceptance (17). Hesitancy toward receiving the COVID-19 vaccine should be addressed. Thus, similar to the current study, several studies were conducted to reveal side effects associated with COVID-19 vaccines in order to provide the general public with data regarding COVID-19 vaccines, which in turn would decrease hesitancy and explain to the public what to expect after the vaccination (8, 13, 15, 20-26).

Global vaccination campaigns have been launched to stop the COVID-19 pandemic. Real-world observing of COVID-19 vaccine safety is still crucial even though clinical trial studies revealed that the majority of COVID-19 vaccines have excellent safety and efficacy profiles. In the current study, sore arm at the injection site, fatigue, discomfort, muscle/joint pain,

drowsiness, and headache were reported by more than half of the participants who experienced side effects (300 out of 533 participants for the first dose, and 267 out of 402 participants for the second dose) after both doses. These findings are in line with several published studies, and are consistent with the side effects listed by the United States Centers for Disease Control and Prevention (CDC) (27). For example, in Saudi Arabia, a survey-based study was conducted to assess the side effects of mRNA-based COVID-19 vaccine, 386 participants completed the survey. The most commonly reported side effects were local pain, fatigue, and muscle pain (79.3%, 42.0%, 39.1%, respectively) (28). Another cross-sectional study conducted in Saudi Arabia documented that the most common side effects reported by the participants were injection site pain, and headache (8). Moreover, a cross-sectional study was conducted among healthcare workers in Czech Republic (15). Injection site pain (89.8%), fatigue (62.2%), headache (45.6%), muscle pain (37.1%), and chills (33.9%) were the most frequently reported side effects experienced by the study participants ( $n = 877$ ). Moreover, the side effects were more common among older participants ( $\leq/\geq 43$ -year-old group) (15). Another cross-sectional study was conducted among healthcare workers ( $n = 803$  received the mRNA-based COVID-19 vaccine), and the most common side effects reported by more than half of the participants

were localized, generalized, and musculoskeletal symptoms (89.5%, 76.0%, 53.3%, respectively) (29). The reported rates of side effects have varied between conducted studies due to differences in race, age, and underlying conditions.

A recent systemic review was undertaken to assess the mRNA-based COVID-19 vaccine side effects. The most frequently reported side effects among the total number of the participants ( $n=10,632$ ) in all articles (107 were screened, and 14 were included) were injection site pain, fatigue, muscle pain, local swelling, and headache (77.3%, 43.0%, 39.7%, 33.6%, 33.3%, respectively) (30). The review findings were in line with the current study findings, as the most commonly reported side effect among the current study's population was sore arm at the injection site.

It is obvious that injection site pain was the most commonly reported side effect among most of the studies conducted on different populations (31-33). Moreover, local pain continues to be the most frequent side effect observed in multiple vaccine trials conducted in the past (34). The reason behind this finding may be explained by the fact that several factors contribute to the pain at the injection site such as the technique used for injection, injection velocity, and vaccine temperature. These factors are challenging to standardize and will have a significant impact on a person's experience (35). It is advised to lower the arm that will be receiving the injection in order to reduce the pain, as an injection into a relaxed muscle causes less pain. Furthermore, it is recommended that the medical staff participating in the vaccination process acquire proper training on the best injection technique to lessen differences in the way individuals experience pain after vaccination (36).

Males and females react to vaccination differently. As documented in a systemic review, the rate of experienced side effects is usually higher in females compared to males (69.8%, 30.2%, respectively) (30). Being female, was a statistically significant factor for experiencing higher number of side effects in two cross-sectional studies conducted in Saudi Arabia (8, 28). Various other published studies observed a gender difference, with females experiencing significantly more side effects compared to males (37, 38). This is consistent with the current study's findings. Moreover, the current study revealed that the female gender is significantly associated with experiencing fatigue, discomfort, chills, and hair loss. This is probably due to a combination of biological factors, such as hormones and genes. Additionally, sex variation in pharmacodynamics and pharmacokinetics have been examined, with females being more susceptible to side effects (39). A medical officer at the CDC's Immunization Safety Office stated that women have more reactions to a range of vaccines. This covers both adult influenza and some childhood vaccinations, such as the hepatitis B, and measles, mumps, and rubella (MMR) vaccines (40). On the other hand, these

findings should not be deemed bad news for women, as firstly, the side effects were mild, and self-limited, and secondly, interestingly, these physical responses indicate that the vaccine is effective and working.

According to the results of the current study, experiencing cough was significantly associated with being older than 30. Several studies assessed the relationship between age and side effects. Baden et al. found that younger participants (18-64 years old) experienced side effects more frequently than participants over the age of 65 (41). Another survey-based study conducted among German healthcare workers revealed that younger participants were more affected by the systemic side effects compared to the older age participants following receiving the mRNA-based COVID-19 vaccine (67.4% vs. 54.5%) (26). The authors' decision to use a different age cutoff in each study may account for the variance in the studies' findings.

More than half of the current study's participants stated that the second dose was accompanied by more severe side effects. Two cross-sectional studies conducted in Saudi Arabia documented similar results, the first one recorded that after the second dose, higher numbers of side effects were reported by the participants compared to the first dose (28), and the second one indicated a significant increase in the proportion of respondents who experienced side effects after receiving the second dose compared to the first dose (8). According to the data collected by the CDC from mRNA-based COVID-19 vaccine recipients in the United States, more side effects were recorded after the second dose. Furthermore, equivalent findings were generated by the FDA (42), and several other studies (37).

## 5. Limitations

This study comes with some limitations. The study was based on an online survey, and this might be a source of selection bias.

However, web-based recruitment of participants was found to be cost-effective, facilitating the reach of people who are otherwise difficult to reach, and representative (43, 44). In Jordan, around 90% of the population have internet access, which makes them easy to reach using online-based questionnaires. Another limitation of this study is that it was conducted while the vaccination campaign was still ongoing in Jordan; therefore, the delayed side effects may not have been reported.

## 6. Conclusions

The current study reveals the side effects associated with the mRNA-based COVID-19 vaccine, which were common, yet, mild, local, and self-limited. The local pain at the injection site was the most commonly reported side effect.

## 7. Declarations

### 7.1. Acknowledgments

None.

### 7.2. Conflict of interest

The author declares no relevant conflicts of interest or financial relationships.

### 7.3. Fundings and supports

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### 7.4. Authors' contribution

R.N: Conceptualization, Methodology, Validation, Formal Analysis, Investigation, Data Curation, Writing - Original Draft Preparation, Writing- Review and Editing.

## References

- Sharma O, Sultan AA, Ding H, Triggler CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Frontiers in immunology*. 2020;11:585354.
- COVID live - Coronavirus statistics - worldometer. [Available from: <https://www.worldometers.info/coronavirus/>]
- Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. *Indian Journal of Clinical Biochemistry*. 2021;36(4):427-39.
- The Jordan Times. Jordan Strategy Forum paper strategises over coronavirus policy 2020 [Available from: <https://www.jordantimes.com/news/local/jordan-strategy-forum-paper-strategises-over-coronavirus-policy>].
- Alqutob R, Al Nsour M, Tarawneh MR, Ajlouni M, Khader Y, Aqel I, et al. COVID-19 crisis in Jordan: Response, scenarios, strategies, and recommendations. *JMIR public health and surveillance*. 2020;6(3):e19332.
- Craven J. COVID-19 Vaccine Tracker 2021 [Available from: <https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker>].
- U.S. Food and Drug Administration. FDA Briefing Document. Pfizer-BioNTech COVID-19 Vaccine 2020 [Available from: <https://www.fda.gov/media/144245/download>].
- El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional study. *International journal of general medicine*. 2021:1389-401.
- Al-Junaidi L. Jordan begins COVID-19 vaccine rollout 2021 [Available from: <https://www.aa.com.tr/en/latest-on-coronavirus-outbreak/jordan-begins-covid-19-vaccine-rollout/2108497>].
- Batarseh YS, Darwish ElHajji FW, Shammas S, Darwish RM, Fakhoury R, Al Haj Ahmad M, et al. Perception and attitude of the public on vaccine practices and pharmacists as immunizers in Jordan. *Journal of Pharmaceutical Health Services Research*. 2021;12(2):114-21.
- Adedeji-Adenola H, Olugbake OA, Adeosun SA. Factors influencing COVID-19 vaccine uptake among adults in Nigeria. *PLoS One*. 2022;17(2):e0264371.
- Enitan S, Oyekale A, Akele R, Olawuyi K, Olabisi E, Nwankiti A, et al. Assessment of knowledge, perception and readiness of Nigerians to participate in the COVID-19 vaccine trial. *International Journal of Vaccines and Immunization*. 2020;4(1):1-13.
- Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkorkhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. *International Journal of Infectious Diseases*. 2021;111:219-26.
- World Health Organization. Vaccines and immunization: What is vaccination? 2021 [Available from: <https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination?adgroupsurvey=adgroupsurvey&gclid=CjwKCAjwoP6LBhB>].
- Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. *Journal of clinical medicine*. 2021;10(7):1428.
- Eng J. Sample size estimation: how many individuals should be studied? *Radiology*. 2003;227(2):309-13.
- Alhassan RK, Aberese-Ako M, Doegah PT, Immurana M, Dalaba MA, Manyeh AK, et al. COVID-19 vaccine hesitancy among the adult population in Ghana: evidence from a pre-vaccination rollout survey. *Tropical Medicine and Health*. 2021;49(1):1-13.
- Al-Turk F, Akour A, Farha RA. The impact of an educational workshop on counteracting hesitancy toward the COVID-19 vaccine among pharmacy students in Jordan. *Journal of Applied Pharmaceutical Science*. 2022;12(8):095-101.
- Qunaibi EA, Helmy M, Basheti I, Sultan I. A high rate of COVID-19 vaccine hesitancy in a large-scale survey on Arabs. *Elife*. 2021;10:e68038.
- Nassar RI, Alnatour D, Thiab S, Nassar A, El-Hajji F, Basheti IA. Short-term side effects of COVID-19 vaccines: A cross-sectional study in Jordan. *Human Vaccines & Immunotherapeutics*. 2022;18(5):2082792.
- Abu-Hammad O, Alduraiddi H, Abu-Hammad S, Alnazawi A, Babkair H, Abu-Hammad A, et al. Side effects

- reported by Jordanian healthcare workers who received COVID-19 vaccines. *Vaccines*. 2021;9(6):577.
22. Dar-Odeh N, Abu-Hammad O, Qasem F, Jambi S, Al-hodhodi A, Othman A, et al. Long-term adverse events of three COVID-19 vaccines as reported by vaccinated physicians and dentists, a study from Jordan and Saudi Arabia. *Human Vaccines & Immunotherapeutics*. 2022;18(1):2039017.
  23. Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2021;15(5):102207.
  24. Omeish H, Najadat A, Al-Azzam S, Tarabin N, Abu Hameed A, Al-Gallab N, et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. *Human vaccines & immunotherapeutics*. 2022;18(1):1981086.
  25. Hatmal MmM, Al-Hatamleh MA, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. *Vaccines*. 2021;9(6):556.
  26. Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt H-P, et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. *Biology*. 2021;10(8):752.
  27. Centers for Disease Control and Prevention. Possible Side Effects 2022 [Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html>].
  28. Mohammed RA, Garout RM, Wahid S, Ayub F, ZinAldin LME, Sultan I. A survey on the side effects of Pfizer/BioNTech COVID-19 vaccine among vaccinated adults in Saudi Arabia. *Cureus*. 2021;13(11).
  29. Kadali RA, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. *International Journal of Infectious Diseases*. 2021;106:376-81.
  30. Dighriri IM, Alhusayni KM, Mobarki AY, Aljerary IS, Alqurashi KA, Aljuaid FA, et al. Pfizer-BioNTech COVID-19 vaccine (BNT162b2) side effects: a systematic review. *Cureus*. 2022;14(3).
  31. Cuschieri S, Borg M, Agius S, Souness J, Brincat A, Grech V. Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta's state hospital. *International journal of clinical practice*. 2021;75(10):e14605.
  32. Riad A, Hocková B, Kantorová L, Slávik R, Spurná L, Stebel A, et al. Side effects of mRNA-based COVID-19 vaccine: nationwide phase IV study among healthcare workers in Slovakia. *Pharmaceuticals*. 2021;14(9):873.
  33. Im JH, Kim E, Lee E, Seo Y, Lee Y, Jang Y, et al. Adverse events with the Pfizer-BioNTech COVID-19 vaccine among Korean healthcare workers. *Yonsei Medical Journal*. 2021;62(12):1162.
  34. Nichol KL, Margolis KL, Lind A, Murdoch M, McFadden R, Hauge M, et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. *Archives of Internal Medicine*. 1996;156(14):1546-50.
  35. Ozdemir L, Akay BN, Akyol A. Effect of methylprednisolone injection speed on the perception of intramuscular injection pain. *Pain Management Nursing*. 2013;14(1):3-10.
  36. Centers for Disease Control and Prevention. Training and Education 2021 [Available from: <https://www.cdc.gov/vaccines/covid-19/training-education/index.html>].
  37. Lee YW, Lim SY, Lee J-H, Lim JS, Kim M, Kwon S, et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. *Journal of Korean medical science*. 2021;36(21).
  38. Alamer E, Alhazmi A, Qasir NA, Alamer R, Areeshi H, Gohal G, et al. Side effects of COVID-19 Pfizer-BioNtech mRNA vaccine in children aged 12–18 years in Saudi Arabia. *Vaccines*. 2021;9(11):1297.
  39. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. *Biology of sex differences*. 2020;11:1-14.
  40. The New York Times. Women Report Worse Side Effects After a Covid Vaccine 2021 [Available from: <https://www.nytimes.com/2021/03/08/health/vaccine-side-effects-women-men.html>].
  41. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New England journal of medicine*. 2021;384(5):403-16.
  42. U.S. Food and Drug Administration. FDA Review of Efficacy and Safety of Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Request 2020 [Available from: <https://www.fda.gov/media/144337/download>].
  43. Fenner Y, Garland SM, Moore EE, Jayasinghe Y, Fletcher A, Tabrizi SN, et al. Web-based recruiting for health research using a social networking site: an exploratory study. *Journal of medical Internet research*. 2012;14(1):e1978.
  44. Cantrell MA, Lupinacci P. Methodological issues in online data collection. *Journal of advanced nursing*. 2007;60(5):544-9.